Sort   by:  
 Page size 
Unknown6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Not available
S-EPMC6615016 | biostudies-literature
UnknownEmpagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7614055 | biostudies-literature
UnknownOverall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Not available
S-EPMC10207856 | biostudies-literature
UnknownNew insights into the genetic etiology of Alzheimer's disease and related dementias.
Not available
S-EPMC9005347 | biostudies-literature
UnknownAdjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer.
Not available
S-EPMC9126186 | biostudies-literature
UnknownLong-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Not available
S-EPMC3596060 | biostudies-literature
UnknownOlfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult Cohort.
Not available
S-EPMC12464792 | biostudies-literature
UnknownMeasurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study.
Not available
S-EPMC11578795 | biostudies-literature
UnknownSex Differences in Long COVID.
Not available
S-EPMC11755195 | biostudies-literature
UnknownSARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.
Not available
S-EPMC7995808 | biostudies-literature
Sort   by:  
 Page size